Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Impax Laboratories, LLC.
483
•Impax Laboratories, LLC.•March 28, 2012

Impax Laboratories, LLC. – FDA 483, Mar 28, 2012

Record Details

This FDA Form 483 document outlines several significant observations made during an inspection, indicating a failure to adhere to Good Manufacturing Practices (GMP) for drug products.

**Key Observations:**

1. **Non-conforming Product Handling:** Drug products that fail to meet established standards and specifications are not being rejected. This indicates a critical lapse in quality control and the potential for sub-standard products to enter the market.

2. **Inadequate Investigations:** Investigations into failures of a batch or its components to meet specifications are not being extended to other batches of the same drug product. This suggests a systemic issue where root causes are not being thoroughly identified and addressed across relevant production runs, potentially allowing recurring defects.

3. **Non-Adherence to Written Procedures (Sampling & Testing):** Written procedures for sampling and testing plans are not being followed for each drug product. This undermines the reliability and validity of quality control data.

4. **Non-Adherence to Written Procedures (Production & Process Control):** Written production and process control procedures are not being followed in the execution of production and process control functions. This indicates a lack of adherence to established manufacturing protocols, which can lead to inconsistent product quality.

5. **Failure to Document and Investigate Discrepancies:** There is a failure to document and investigate unexplained discrepancies that arise during manufacturing and Quality Control (QC) analytical testing, specifically referencing the issues detailed in Observations 1 to 4.

Company
Impax Laboratories, LLC.
Inspection date
March 28, 2012
Office
San Francisco District Office
People
  • Peter E. Baker (President)
  • William V. Millar (Self-employed)
View Company Profile

ID · bacb80ad-e9b7-4bae-a3d7-077a816b13df

Other documents for Impax Laboratories, LLC.
  • 483 - 2016-05-04May 4, 2016
  • 483 - 2013-02-28February 28, 2013
  • CRL

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Impax Laboratories, LLC.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.